Primus In News
Pharma stocks rise as US considers exempting generics from tariffs
09-10-2025
Shravan Shetty, Managing Director, Primus Partners, highlighted the importance of India's $10 billion generic drug exports to the US for domestic pharma companies. He emphasized that potential tariff exemptions on generics would protect this vital revenue stream. Additionally, he said the recent market recovery reflects a rebound from previous declines, with further growth likely as generics gain traction in the US due to widening price gaps with branded drugs.
Explore Related Insights
- PhysicsWallah share listing tomorrow: Analysts suggest long-term hold with partial profit booking; check GMP
- Budget 2021-2022 : Why India needs a goods education budget?
- Indian carriers may fly into delivery shortfall in 2025 as Boeing battles production issues
- Govt must support India’s manufacturing sector
